openPR Logo
Press release

Propelled by Innovative Devices Patient Self-Administration is Transforming the Market for Injectables

10-11-2016 05:57 PM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – Rapid changes in the therapeutic drug sector are challenging pharmaceutical developers in a number of functional areas. In this mix are the evolving transformations within the healthcare systems and services segment, the escalating presence of biologicals in both revenue and total drug count, the transition from traditional caregiver models to self-dosing, and the influence of direct-to-consumer marketing on promotional programs. One major effect of these trends is the absolute increase of drugs supplied in patient-targeted injection devices, a dynamic that includes as-developed therapeutics as well as post-launch formulation and packaging migration from vials to prefilled devices.

Changes in the way drugs are designed and developed are most evident in injectable drug therapies for a host of chronic conditions. Because of the ongoing need for repeat dosing posed by these disease indications, they represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver. For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes.

In recent years, the number of protein-based pharmaceuticals reaching the marketplace has increased exponentially. Because of stability and shelf life factors, therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed. Alternatively, proteins can be formulated as powders. These lyophilized proteins must be reconstituted prior to injection. For lyophilized drugs intended for self-administration, reconstitution must occur at the point of use. To address this requirement, a number of integrated and adaptive devices and systems have been designed to reconstitute lyophilized drugs immediately prior to delivery.

The continued emphasis on healthcare cost containment and the availability of drug therapies for previously untreatable ailments will drive double-digit growth in the market for self-injection of parenteral drugs. Consumers with diabetes are accustomed to the need for self-administration of drugs via injection. More recently, therapies for chronic conditions such as hormone deficiency, reproductive health and autoimmunity have demonstrated the market potential for self-administration of injectable drugs. Personalized medicine and therapeutic vaccines will introduce a new and expanding population to the process of home drug treatment.

A major factor in the growth of home healthcare is the convergence of managed care initiatives to control rising healthcare costs and the aging population. The number of Americans over age 85 is increasing faster than any other group. Home care medical devices represent the fastest growing segment of the medical device industry. With a continuing reduction in hospital stays for most conditions, home health care is becoming more and more common. Self-care in the home can give a sense of security and comfort that cannot be reproduced in a healthcare facility. With advances in medicine, home healthcare can be safe and effective.

It’s been over a decade since pharmaceutical companies began marketing drugs directly to consumers. During that time, what started as a novelty has become a major marketing spend channel for the industry. The effects have become ubiquitous and easy to identify. These impacts will increase as DTC budgets at most major drug companies continue to rise on a year-to-year basis.

The evolving subcutaneous self-administration landscape is detailed in a new and comprehensive report researched and written by Greystone Research Associates. Subcutaneous Self-Administration Markets to 2024 analyzes the global market for injectable drugs designed for subcutaneous self-administration. The report analyzes demand drivers, development factors, market considerations, and strategic and economic factors, and provides profiles of market sector participants.

More information is available at

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Propelled by Innovative Devices Patient Self-Administration is Transforming the Market for Injectables here

News-ID: 371364 • Views: 587

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases

More Releases for Amherst

Intradermal Drug Delivery Gaining Momentum as Technology and Benefits Converge
(Amherst, NH) – Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these
New Aircraft Designs Creating Opportunities for High Performance Aerospace Coati …
(Amherst, NH) – As aerospace manufacturers and their engineering teams push the design envelope to create aircraft with better fuel efficiency and lower maintenance requirements, they are relying increasingly on engineered materials for a growing list of structural and non-structural elements and components. This trend is changing the way aircraft are developed, produced and maintained. It’s also presenting opportunities for specialty materials suppliers with products that can improve production
Evolution in Markets for Radiation Curable Coatings Creating Risks and Opportuni …
(Amherst, NH) – Recent advances in materials and equipment are creating new demand for radiation curable coatings in a number of industrial applications. This new demand is occurring as several technology advances are being brought into the marketplace. By removing some of the key limitations of radcure coatings, these advances are enabling radcure coatings to meet unique application requirements, opening up a number of new opportunities. Technical advances that are having
Drug Delivery Coatings Creating Opportunities for Developers and Practitioners
(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes. Currently more than two dozen companies are pursuing specialty coatings capable of delivering APIs. These participants are exploring a
Adros Energy Expands Clean Energy Business with Energy Audit Services and opens …
Adros Energy; a leading green energy company in New England, announced today that they are opening a new headquarters in Amherst, NH after a successful 1st year of operation in the renewable energy market. The company was founded in January of 2009 and has found success during the incubation period of the company. The infrastructure building of the company in 2009 includes: • Revenue generation from its solar PV,
Esensors Adds New Websensor Features
July 22, 2008 – Amherst, NY – EM01B Websensor is an environmental sensor that provides accurate measurement of temperature, relative humidity and light over a network. This month, Esensors adds some new features to EM01B Websensor. The free Websensor Data Logger now enables users to easily export the data to other software tools for analysis. This allows the flexibility to generate custom data views and make data collection more